Cell Guidance Systems Blog

Thalidomide, the trailblazing molecular glue degrader

Thalidomide, the trailblazing molecular glue degrader

From 1957 to 1961, Thalidomide, a small molecule drug, was prescribed to treat a range of conditions in pregnant women including morning sickness. The developmental abnormalities that it caused in the developing foetus made the drug synonymous with pharmaceutical negligence. Despite this, in 1988, thalidomide was approved for the safe treatment of leprosy and cancer.

Read More

Could FGF17 rejuvenate the brain?

Could FGF17 rejuvenate the brain?

Rapidly increasing public and private research funding is increasing our understanding of the ageing process. This is starting to yield results that could allow therapeutic intervention. Surprisingly, it seems a single cytokine could modulate brain ageing. Could we be on the verge of therapies that will extend the limits of human health?

Read More

Zebrafish embryo surprised by morphogen cluster synergy

Zebrafish embryo surprised by morphogen cluster synergy

The development of complex multicellular forms, such as this zebrafish, relies on the activity of morphogen gradients acting differentially on individual cell surface receptors. The way receptors and their ligands present themselves to each other, either dispersed or in clusters, has a dramatic impact on the consequences of their interaction.

Read More

Green fingers: Plant scaffolds for body parts

Green fingers: Plant scaffolds for body parts

Wood, bamboo and other plant-derived materials are widely used to provide structural integrity for buildings. It turns out that plant-derived scaffolds can also be used, on a much smaller scale, to support the culture of cells grown in 3D. Importantly, as well as providing structure, plant structures can provide vasculature, on a similar scale to our own, enabling nutrients and signalling molecules to be carried to cells that are distant from the surface.

Read More

Cytokine storm in a teacup: Growth factor dynamics in cell culture

Cytokine storm in a teacup: Growth factor dynamics in cell culture

Recombinant cytokines and other growth factors underpin cell culture and are as important to biotechnology as semi-conductors are to information technology. They also provide a source of cell-based assay variability. Understanding cytokine dynamics is important to the design of better cell-based assays and manufacturing systems.

Read More

Exosome dominoes: How acute pancreatitis leads to lung injury

Exosome dominoes: How acute pancreatitis leads to lung injury

Acute pancreatitis (AP) is a sudden and severe inflammation of the pancreas sometimes caused by gallstones. In the most severe cases, AP can also lead to injury of the lung. The pathway from pancreatic disease to lung injury is anything but direct and a fundamental role for exosomes has emerged.

Read More

Cancer wars: the return of the cytokine

Cancer wars: the return of the cytokine

In the 1890s, William Coley (pictured) pioneered techniques that boost immune activity against cancer by injecting pathogens into cancer patients to stimulate their immune system. The modern emergence of onco-immunotherapy began with the therapeutic development of cytokines. These messenger proteins modulate both innate and adaptive immunity. Although they have been overshadowed by checkpoint inhibitors for the last decade, there is renewed interest in targeting and harnessing cytokines for cancer immunotherapy.

Read More

Gut instincts: the mucosal immune system treads a thin line

Gut instincts: the mucosal immune system treads a thin line

Mucosal surfaces are the primary interface between an individual and pathogens and are particularly vulnerable to infection. Yet, they also come into regular contact with a host of antigens that need to be tolerated. To allow tolerance and deal with a constant threat of infection, a dynamic and complex array of immune mechanisms provide a finely calibrated first response to these invasive microbial threats.

Read More

Cancer models are getting better

Cancer models are getting better

More than any other disease, the complexity of cancer has frustrated the development of effective therapeutics. The varying and evolving landscape of genetic changes between and within tumors and the complex interaction of the cancer cells with the immune system make this disease extremely difficult to simulate. A range of models now exists that better replicate cancers complexity.

Read More

Whatever happed to Endostatin?

Whatever happed to Endostatin?

Cancer drug candidates sometimes emerge with exceptional promise but ultimately fall short. In the late 1990s, endostatin gained huge prominence and was widely viewed as an exceptional cancer drug candidate. But things didn’t quite work out. Although endostatin is now approved by the FDA, in the West it is largely forgotten, eclipsed by newer treatments. But look East, notably to China, and endostatin is very much at the forefront of cancer therapy, particularly in combination with chemotherapy. Why have its fortunes varied geographically and will it ever make a global impact?

Read More